International Clinical Trial: A phase II clinical study of briitinib in combination with PLB1004 first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations and MET abnormalities

Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127991) titled 'A phase II clinical study of briitinib in combination with PLB1004 first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations and MET abnormalities' on July 12.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)

Condition: Locally advanced or metastatic non-small cell lung cancer with EGFR mutations and MET abnormalities

Intervention: Matched group:Osimertinib Mesylate Tablets , 80mg, once daily, PO

Recruitment Status: Not Recruiting

Phase: 2

Dat...